Home › Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
 

Keywords :   


Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients

2015-09-02 07:45:41| drugdiscoveryonline News Articles

Highland Therapeutics Inc. (“Highland”) announced recently that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has dosed the first patient in the second of two pivotal studies of HLD-200

Tags: trial patients adhd announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Hurricane Isaac Graphics
29.09Hurricane Isaac Forecast Discussion Number 13
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Wind Speed Probabilities Number 13
29.09Hurricane Isaac Public Advisory Number 13
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Tropical Storm Joyce Wind Speed Probabilities Number 7
29.09Tropical Storm Joyce Forecast Discussion Number 7
More »